Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Clemens Stoffregen"'
Autor:
Thorsten Otto, Achim Wöckel, Agnieszka Korfel, Mattea Reinisch, Clemens Stoffregen, Norbert Marschner
Publikováno v:
Breast Care (Basel)
Introduction: Integration of patient preferences into shared decision making improves disease-related outcomes, but such data from patients with advanced breast cancer (aBC) are limited. The objective of this study was to demonstrate the relative imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eac25d88583f2787100eb4e44cee4fc
https://doi.org/10.1159/000513139
https://doi.org/10.1159/000513139
Autor:
Achim Wöckel, Thorsten Otto, Agnieszka Korfel, Clemens Stoffregen, Mattea Reinisch, Norbert Marschner
Publikováno v:
Cancer Research. 80:P1-17
Objective: This study aimed to identify patient preferences in aBC related to cancer treatment characteristics, i.e. to determine the relevance of gained lifetime (OS) and time to progression (PFS) in relation to quality of life (QoL) and therapy-ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f3de2bea176395186de73badd6fdea4
https://doi.org/10.1158/1538-7445.sabcs19-p1-17-08
https://doi.org/10.1158/1538-7445.sabcs19-p1-17-08
Autor:
Miguel Martin, Gregory L Price, Jens Huober, Stephen R. D. Johnston, Eriko Tokunaga, Sarah Shekarriz, M. Corona Gainford, Valerie Andre, Matthew P. Goetz, Masakazu Toi, Clemens Stoffregen, In Hae Park
Publikováno v:
The Oncologist
Background MONARCH 3, a phase III trial (NCT02246621) of postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), previously demonstrated significantly im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f015e98bdcc3668c6d6e123d88df48
https://pubmed.ncbi.nlm.nih.gov/32536013
https://pubmed.ncbi.nlm.nih.gov/32536013
Autor:
EM Grischke, Sarah Shekarriz, Masakazu Toi, Joohyuk Sohn, Valerie Andre, Gregory L Price, Gebra Cuyun Carter, Peter A. Kaufman, Patrick Neven, George W. Sledge, Clemens Stoffregen
Publikováno v:
The Oncologist
Background In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus fulvestrant in patients with hormone receptor‐positive (HR+), HER2‐negative advan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45f893ac212ab7c69f433f4ac56ad26
https://lirias.kuleuven.be/handle/123456789/650756
https://lirias.kuleuven.be/handle/123456789/650756
Autor:
Thiery Gorlia, Marc Sanson, Clemens Stoffregen, Martin J. van den Bent, Myriam Gharib, Christina Lai, Denis Lacombe, Walter Taal, Roy Rampling, Rodney Decker
Publikováno v:
Neuro-Oncology, 14(3), 344-350. Oxford University Press
We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was conducted in patients with recurrent glioblast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a888199d5eaf9887e421b7039cdfdbe
https://pure.eur.nl/en/publications/9bc3824b-3247-4fa4-9840-14ad8ddd7010
https://pure.eur.nl/en/publications/9bc3824b-3247-4fa4-9840-14ad8ddd7010
Autor:
Clemens Stoffregen, Robert A. Wolff, Anwar Hossain, Martin Fuchs, Steven J. Nicol, Maria Di Bartolomeo, Volker Heinemann
Publikováno v:
Cancer. 118:4132-4138
BACKGROUND: Enzastaurin and bevacizumab have demonstrated synergistic antitumor effects and, in phase 1 studies, the combination was well tolerated. This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f90b776e69f40f9fec6c290dead2945
https://doi.org/10.1002/cncr.26692
https://doi.org/10.1002/cncr.26692
Autor:
Andreas, Böhle, Herbert, Leyh, Christian, Frei, Michael, Kühn, Reinhold, Tschada, Tobias, Pottek, Walter, Wagner, Helmut H, Knispel, Wolfgang, von Pokrzywnitzki, Ferruh, Zorlu, Karin, Helsberg, Birgit, Lübben, Victoria, Soldatenkova, Clemens, Stoffregen, Hartwig, Büttner, Zuhtu, Tansug
Publikováno v:
European Urology. 56:495-503
Background Recurrence prophylaxis with intravesical gemcitabine (GEM) was effective and safe in patients with non-muscle-invasive bladder cancer (NMIBC); efficacy as single-shot instillation remains to be proved. Objective To compare the efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c57b3e88ad8c0291376d63fb93f0e1
https://doi.org/10.1016/j.eururo.2009.06.010
https://doi.org/10.1016/j.eururo.2009.06.010
Autor:
Clemens Stoffregen, Norman Rieger, Ute Ohnmacht, Jürgen Fischer, Christian Manegold, Marius Zemaitis, Harald Lahm
Publikováno v:
Lung Cancer. 56:115-123
The epigenetic inactivation of genes plays an important role in lung cancer. We have investigated the methylation status of the promoter region of seven genes (APC1A, DAPK, FHIT, p14(ARF), p16(INK4a), RARbeta, RASSF1A) in serum DNA of NSCLC patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f50f48eb76e115ae6a544db9a879a21e
https://doi.org/10.1016/j.lungcan.2006.11.016
https://doi.org/10.1016/j.lungcan.2006.11.016
Autor:
Amir Abdollahi, Marc Bischof, Klaus J. Weber, Ping Gong, J.ürgen Debus, Peter E. Huber, Kenneth E. Lipson, Clemens Stoffregen
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 60:1220-1232
Purpose: This is the first preclinical report evaluating a trimodal therapy consisting of irradiation, chemotherapy, and antiangiogenesis in the context of a multimodal anticancer strategy. The combination of the folate antimetabolite pemetrexed, SU5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcaa70dfdd3d0d90540ecf4c8fa394cc
https://doi.org/10.1016/j.ijrobp.2004.07.689
https://doi.org/10.1016/j.ijrobp.2004.07.689
Autor:
Clemens Stoffregen, Horst-Günter Rau, Volker Heinemann, Eckhart Dühmke, Martin Thoma, Andreas C.C. Wagner, Ralf Wilkowski
Publikováno v:
Strahlentherapie und Onkologie. 179:78-86
Die simultane Radiochemotherapie unter Verwendung von Gemcitabin scheint bei der Behandlung des Pankreaskarzinoms ein hoffnungsvoller Ansatz, da Gemcitabin als Monosubstanz oder in Kombination mit anderen Zytostatika eine verbesserte Wirksamkeit beim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bc5a7eba1f4af4c1dc606d18126d044
https://doi.org/10.1007/s00066-003-1036-x
https://doi.org/10.1007/s00066-003-1036-x